Published: July 26, 2005

Addison-Davis Diagnostics Attending the American Correctional Association's 135th Congress of Correction

Addison-Davis Diagnostics, Inc. (OTC BB: ADDI) is pleased to announce that Bill Hallagan, VP of Marketing and Sales for Ohio Surgical, will be attending the American Correctional Association's 135th Congress of Correction, August 6-11, 2005, at the Baltimore Convention Center. This event will be an opportunity to interact with other industry leaders and prospective clients who will be exploring the latest in products and services available. The company expects to present its drug testing product to dozens of correctional institutions on a national scale throughout the week.

Addison-Davis Diagnostics recently signed a strategic sales and marketing agreement with Ohio Surgical, LLC. Ohio Surgical will be responsible for setting up and maintaining sales and distribution channels for "Drug Stop," the Addison-Davis on site drug screening test, which has already received FDA 510K and Over-The-Counter Clearance.

About Addison-Davis

Addison-Davis Diagnostics, Inc. is responding to industry demands by supplying quick response diagnostic tests that are user friendly, produce fast simple results and are less costly, less problematic and less time consuming. Addison-Davis is currently focused on bringing fast and reliable "Point-of-care" Diagnostic Testing through the use of its patented technology to Healthcare Professionals, Hospitals, certain branches of the Government and the Workplace environment for drugs-of-abuse and medical conditions and diseases.

For more information please visit our website www.addisondavis.com or contact Matt Maguire, 1-866 THE APPL(E).

Safe Harbor

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.